Nucana (NCNA) has released an update.
NuCana plc has announced the US Patent and Trademark Office granted a new patent for NUC-7738, a novel anti-cancer agent showing promising results in a Phase 2 study for PD-1 inhibitor resistant melanoma. The patent significantly strengthens the drug’s intellectual property portfolio, which includes over 80 issued patents globally. This comes on the heels of positive data presented at the ESMO Congress, highlighting NUC-7738’s potential to improve outcomes for patients with metastatic melanoma.
For further insights into NCNA stock, check out TipRanks’ Stock Analysis page.
